HSD17B14

Across TCGA pan-cancer cohorts, HSD17B14 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HSD17B14 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HSD17B14 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HSD17B14 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC and LSCC are the cancer types where HSD17B14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	1.000	0.779	.033	12	view →
LSCC	DFS	Quartile	All	0.526	0.845	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

HSD17B14–CCRCC (OS)

Open the CCRCC breakdown →